Teva has received US Food and Drug Administration (FDA) approval for its ProAir Digihaler (albuterol sulfate) 117μg inhalation powder device, “the first and only digital inhaler with built-in sensors which connects to a companion mobile application and provides inhaler-use information to people with asthma and chronic obstructive pulmonary disease (COPD)”.
Teva Obtains Approval For ProAir Digihaler In The US
Receiving FDA approval for its ProAir Digihaler (albuterol sulfate) inhalation powder is a “significant milestone” for Teva, as the firm reveals plans to make the device available in limited geographies in 2019, with a nationwide US launch set for 2020.
